当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.

The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.

Abstract：

:Deregulated methylation of cytosine in DNA is a frequent finding in malignancy that is reflected by general genomic hypomethylation and regional hypermethylation that includes the myogenic gene Myf-3. In this study of 198 DNA samples from 186 patients with a wide range of lymphoproliferative disorders (LPD), the methylation status of Myf-3 was assessed to evaluate its significance in the diagnosis of malignant LPD. DNA was digested with the restriction endonucleases HpaII and MspI, and using the Southern blot (SB) technique, the size and density of fragments that hybridized with a Myf-3 probe were used to assign the methylation status. None of the samples from 45 patients from a wide age range with benign LPDs had evidence of altered Myf-3 methylation and there was no age-related methylation change. By contrast, 115/123 (93%) of samples from patients with non-Hodgkin lymphoma (NHL) or lymphoid leukemia had increased Myf-3 methylation. There was no methylation alteration in 22/24 (92%) of samples from patients with Hodgkin lymphoma (HL), nor in five of six samples from LPDs that had atypical histopathologic features which were not diagnostic of lymphoma, while the remaining sample of atypical LPD had hypermethylated Myf-3 fragments. There was an association between increasing Myf-3 methylation and higher histopathologic grade of malignancy within specific lymphoma categories. It is concluded that the detection of increased Myf-3 methylation is a sensitive and specific test of malignancy which may complement other molecular methods that are currently used for the assessment of clonality. It may be of particular diagnostic use in natural killer (NK) and null cell malignancies for which other indicators of clonality are lacking. Furthermore, methylation status may prove to be of potential prognostic value.

journal_name

Leukemia

journal_title

Leukemia

authors

Taylor JM,Kay PH,Spagnolo DV

doi

10.1038/sj.leu.2402080

subject

Has Abstract

pub_date

2001-04-01 00:00:00

pages

583-9

issue

4

eissn

0887-6924

issn

1476-5551

journal_volume

15

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.

    abstract：:Chromosomal breakpoints associated with malignancy are known to cluster at particular regions of the karyotype. Based on a review of the literature we have identified a novel leukaemia syndrome associated with translocations involving 8p11. This syndrome is distinct from the previously described translocation t(8;16)(...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Macdonald D,Aguiar RC,Mason PJ,Goldman JM,Cross NC

    更新日期：1995-10-01 00:00:00

  • Quality assurance in RT-PCR-based BCR/ABL diagnostics--results of an interlaboratory test and a standardization approach.

    abstract：:Here we describe the results of an interlaboratory test for RT-PCR-based BCR/ABL analysis. The test was organized in two parts. The number of participating laboratories in the first and second part was 27 and 20, respectively. In the first part samples containing various concentrations of plasmids with the ela2, b2a2 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401899

    authors： Burmeister T,Maurer J,Aivado M,Elmaagacli AH,Grünebach F,Held KR,Hess G,Hochhaus A,Höppner W,Lentes KU,Lübbert M,Schäfer KL,Schafhausen P,Schmidt CA,Schüler F,Seeger K,Seelig R,Thiede C,Viehmann S,Weber C,Wilhelm

    更新日期：2000-10-01 00:00:00

  • Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

    abstract：:We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies including CD20 tar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.224

    authors： Wong KK,Gascoyne DM,Brown PJ,Soilleux EJ,Snell C,Chen H,Lyne L,Lawrie CH,Gascoyne RD,Pedersen LM,Møller MB,Pulford K,Murphy D,Green TM,Banham AH

    更新日期：2014-02-01 00:00:00

  • Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.

    abstract：:The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia. In contrast to the more common oncogenic ABL1 fusion BCR-ABL1, NUP214-ABL1 localizes to the nuclear pore complexes and has attenuated transforming properties in hematopoietic cells and in mouse bone m...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.242

    authors： De Keersmaecker K,Versele M,Cools J,Superti-Furga G,Hantschel O

    更新日期：2008-12-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract：:Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.93

    authors： Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期：2014-10-01 00:00:00

  • MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

    abstract：:MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.186

    authors： Giles FJ,Swords RT,Nagler A,Hochhaus A,Ottmann OG,Rizzieri DA,Talpaz M,Clark J,Watson P,Xiao A,Zhao B,Bergstrom D,Le Coutre PD,Freedman SJ,Cortes JE

    更新日期：2013-01-01 00:00:00

  • The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ('Ponte di legno meeting') report: Vienna, Austria, April 27-28, 2005.

    abstract：:The International Acute Lymphoblastic Leukemia Working Group, the so-called 'Ponte di Legno Workshop' has led to substantial progress in international collaboration in leukemia research. On April 27-28, 2005, the 8th Meeting was held in Vienna, Austria, to continue the discussions about special common treatment elemen...

    journal_title：Leukemia

    pub_type：

    doi：10.1038/sj.leu.2404016

    authors： Gadner H,Masera G,Schrappe M,Eden T,Benoit Y,Harrison C,Nachman J,Pui CH

    更新日期：2006-01-01 00:00:00

  • A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

    abstract：:This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.34

    authors： Brandwein JM,Hedley DW,Chow S,Schimmer AD,Yee KW,Schuh AC,Gupta V,Xu W,Kamel-Reid S,Minden MD

    更新日期：2011-06-01 00:00:00

  • A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

    abstract：:All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0892-z

    authors： Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

    更新日期：2020-06-19 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract：:Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.leu.2405087

    authors： San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期：2008-04-01 00:00:00

  • Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

    abstract：:Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 consecutive, not previously transplanted patients who were enrolled in phase II studies of imatinib. Of 30 patient...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2402770

    authors： Wassmann B,Pfeifer H,Scheuring U,Klein SA,Gökbuget N,Binckebanck A,Martin H,Gschaidmeier H,Hoelzer D,Ottmann OG

    更新日期：2002-12-01 00:00:00

  • Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.

    abstract：:Patients with acute myelogenous leukemia or myelodysplastic syndrome may respond to farnesyl transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients. FTIs prevent the attachment of a lipid farnesyl moiety to dependent proteins prior to their insertion into the plasma m...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403063

    authors： Liesveld JL,Lancet JE,Rosell KE,Menon A,Lu C,McNair C,Abboud CN,Rosenblatt JD

    更新日期：2003-09-01 00:00:00

  • Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.

    abstract：:Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the long arm of chromosome 5 (del(5q)), lenalidomide exerts hematological and cytogenetic effects, but the ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.296

    authors： Matsuoka A,Tochigi A,Kishimoto M,Nakahara T,Kondo T,Tsujioka T,Tasaka T,Tohyama Y,Tohyama K

    更新日期：2010-04-01 00:00:00

  • Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions.

    abstract：:Polymerase chain reaction (PCR) techniques utilizing clonospecific T cell receptor (TCR) gamma or delta junctional regions constitute broadly applicable strategies to study the clinical relevance of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients. For the majority of cases current PCR pro...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Seriu T,Hansen-Hagge TE,Erz DH,Bartram CR

    更新日期：1995-02-01 00:00:00

  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

    abstract：:RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41375-019-0603-9

    authors： Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

    更新日期：2020-03-01 00:00:00

  • Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells.

    abstract：:We investigated the effect of ubenimex on the growth and differentiation of U937 cells, a histiocytic lymphoma cell line. Ubenimex is a dipeptide ((2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine) and an inhibitor of aminopeptidase B produced by Streptomyces olivoreticuli. Ubenimex inhibited the proliferation of U9...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Murata M,Kubota Y,Tanaka T,Iida-Tanaka K,Takahara J,Irino S

    更新日期：1994-12-01 00:00:00

  • Faconi anemia and bone marrow clonal chromosome abnormalities.

    abstract：:Clonal chromosome abnormalities were detected in bone marrow cells of 20 patients with Fanconi anemia investigated at various stages of the disease. Two presented with acute leukemia, six with myelodysplastic syndrome, and 12 had minor or no morphological abnormalities of hematopoietic cells. Abnormalities of chromoso...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Maarek O,Jonveaux P,Le Coniat M,Derré J,Berger R

    更新日期：1996-11-01 00:00:00

  • Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

    abstract：:Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0413-0

    authors： Pfeifer H,Cazzaniga G,van der Velden VHJ,Cayuela JM,Schäfer B,Spinelli O,Akiki S,Avigad S,Bendit I,Borg K,Cavé H,Elia L,Reshmi SC,Gerrard G,Hayette S,Hermanson M,Juh A,Jurcek T,Chillón MC,Homburg C,Martinelli G,

    更新日期：2019-08-01 00:00:00

  • Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes.

    abstract：:The expression of the myeloperoxidase (MPO) gene was studied, by means of Northern blot analysis in 14 cases of acute myeloid leukemia (AML), 11 cases of chronic myeloid leukemia (CML), and 6 cases of CML blast crisis, and in HL60 cells before and after induction of terminal differentiation with retinoic acid (RA), ph...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Ferrari S,Tagliafico E,Ceccherelli G,Selleri L,Calabretta B,Donelli A,Temperani P,Sarti M,Sacchi S,Emilia G

    更新日期：1989-06-01 00:00:00

  • Decrease of memory T helper cells (CD4+ CD45R0+) in hairy cell leukemia.

    abstract：:Patients with hairy cell leukemia (HCL) are prone to opportunistic infections, which suggests an impaired T-cell functioning. To investigate a possible mechanism of such an impairment, we determined the numbers of naive and memory T cells by measuring the expression of CD45R0 on CD4+ and CD8+ T cells in 23 HCL patient...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： van der Horst FA,van der Marel A,den Ottolander GJ,Kluin-Nelemans HC

    更新日期：1993-01-01 00:00:00

  • Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients.

    abstract：:The translocation (14;18)(q32;q21) is the hallmark of follicular lymphoma (FL). However, conventional cytogenetics and PCR techniques fail to detect it in at least 10% of cases. In order to evaluate the true incidence of this translocation in FL, we analyzed 63 patients with FL, and 17 patients with diffuse large cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402739

    authors： Godon A,Moreau A,Talmant P,Baranger-Papot L,Geneviève F,Milpied N,Zandecki M,Avet-Loiseau H

    更新日期：2003-01-01 00:00:00

  • Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

    abstract：:We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400768

    authors： Matsuo Y,MacLeod RA,Uphoff CC,Drexler HG,Nishizaki C,Katayama Y,Kimura G,Fujii N,Omoto E,Harada M,Orita K

    更新日期：1997-09-01 00:00:00

  • KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

    abstract：:To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.330

    authors： Clipson A,Wang M,de Leval L,Ashton-Key M,Wotherspoon A,Vassiliou G,Bolli N,Grove C,Moody S,Escudero-Ibarz L,Gundem G,Brugger K,Xue X,Mi E,Bench A,Scott M,Liu H,Follows G,Robles EF,Martinez-Climent JA,Oscier D,Wa

    更新日期：2015-05-01 00:00:00

  • The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype.

    abstract：:To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403010

    authors： Matsuo T,Kuriyama K,Miyazaki Y,Yoshida S,Tomonaga M,Emi N,Kobayashi T,Miyawaki S,Matsushima T,Shinagawa K,Honda S,Ohno R,Japan Adult Leukemia Study Group.

    更新日期：2003-08-01 00:00:00

  • Trial of IFN or STI571 before proceeding to allografting for CML?

    abstract：:Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401874

    authors： Hehlmann R

    更新日期：2000-09-01 00:00:00

  • Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

    abstract：:Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultane...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404139

    authors： Ross DM,Branford S,Moore S,Hughes TP

    更新日期：2006-04-01 00:00:00

  • CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.

    abstract：:The presence of rare malignant stem cells supplying a hierarchy of malignant cells has recently been reported. In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction. To understand the origin of malignant cells in primary human B-pre...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.83

    authors： Kong Y,Yoshida S,Saito Y,Doi T,Nagatoshi Y,Fukata M,Saito N,Yang SM,Iwamoto C,Okamura J,Liu KY,Huang XJ,Lu DP,Shultz LD,Harada M,Ishikawa F

    更新日期：2008-06-01 00:00:00

  • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.

    abstract：:A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelogenous leukemia. One hundred and thirty-one patients stratified by age...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Vogler WR,McCarley DL,Stagg M,Bartolucci AA,Moore J,Martelo O,Omura GA

    更新日期：1994-11-01 00:00:00

  • Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-020-0782-4

    authors： Weisberg E,Meng C,Case A,Sattler M,Tiv HL,Gokhale PC,Buhrlage S,Wang J,Gray N,Stone R,Liu S,Bhagwat SV,Tiu RV,Adamia S,Griffin JD

    更新日期：2020-09-01 00:00:00

  • Genetic instability of human cells with DNA related to human retrovirus.

    abstract：:To elucidate the role of HTLV-I in human neoplasia, DNA was extracted from tumor tissues, cultured cells, and/or sera from 20 HTLV-I seropositive and from 10 seronegative cancer patients, subjected to PCR-PAGE, and analyzed by Southern hybridization. HTLV-I related sequences were detected in tumors of the seropositive...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Maruyama K,Fukushima T,Mochizuki S,Kawamura K,Koshikawa N,Miyauchi M,Nakano M

    更新日期：1994-04-01 00:00:00